Author

Stephan Miehlke

European guideline on the management of microscopic colitis
European guideline on the management of microscopic colitis

Stephan Miehlke

A 12-WEEK TREATMENT WITH BUDESONIDE ORODISPERSIBLE TABLETS IN THE EOS-1 TRIAL FOR INCOMPLETE RESPONDERS SIGNIFICANTLY IMPROVES BOTH INFLAMMATORY AND FIBROSTENOTIC ENDOSCOPIC FEATURES IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS
A 12-WEEK TREATMENT WITH BUDESONIDE ORODISPERSIBLE TABLETS IN THE EOS-1 TRIAL FOR INCOMPLETE RESPONDERS SIGNIFICANTLY IMPROVES BOTH INFLAMMATORY AND FIBROSTENOTIC ENDOSCOPIC FEATURES IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS

A 12-WEEK TREATMENT WITH BUDESONIDE ORODISPERSIBLE TABLETS IN THE EOS-1 TRIAL FOR INCOMPLETE RESPONDERS SIGNIFICANTLY IMPROVES BOTH INFLAMMATORY AND FIBROSTENOTIC ENDOSCOPIC FEATURES IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS
A 12-WEEK TREATMENT WITH BUDESONIDE ORODISPERSIBLE TABLETS IN THE EOS-1 TRIAL FOR INCOMPLETE RESPONDERS SIGNIFICANTLY IMPROVES BOTH INFLAMMATORY AND FIBROSTENOTIC ENDOSCOPIC FEATURES IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS

Stephan Miehlke  et al.

European Guideline on Microscopic colitis - UEG and EMCG consensus recommendations
European Guideline on Microscopic colitis - UEG and EMCG consensus recommendations

Stephan Miehlke

Guidelines Webinar # 3 | Microscopic colitis: From guidelines to clinical practice
Guidelines Webinar # 3 | Microscopic colitis: From guidelines to clinical practice

Stephan Miehlke  et al.

REAL-WORLD DATA ON EFFICACY AND SAFETY OF TOPICAL BUDESONIDE THERAPY (ORODISPERSIBLE TABLET) IN INDUCTION AND MAINTENANCE THERAPY IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS
REAL-WORLD DATA ON EFFICACY AND SAFETY OF TOPICAL BUDESONIDE THERAPY (ORODISPERSIBLE TABLET) IN INDUCTION AND MAINTENANCE THERAPY IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS

Stephan Miehlke  et al.

European guidelines on microscopic colitis: UEG and European Microscopic Colitis Group (EMCG) statements and recommendations
European guidelines on microscopic colitis: UEG and European Microscopic Colitis Group (EMCG) statements and recommendations

Stephan Miehlke  et al.

BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE FIRST 48-WEEKS OPEN-LABEL EXTENSION PHASE OF THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL
BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE FIRST 48-WEEKS OPEN-LABEL EXTENSION PHASE OF THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Stephan Miehlke  et al.

BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 96-WEEKS OPEN-LABEL EXTENSION PHASE FOLLOWINGTHE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL
BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 96-WEEKS OPEN-LABEL EXTENSION PHASE FOLLOWINGTHE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Stephan Miehlke  et al.

BUDESONIDE ORODISPERSIBLE TABLETS ARE HIGHLY EFFECTIVE FOR RE-INDUCTION OF CLINICAL REMISSION IN RELAPSING ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE EOS-2 TRIAL
BUDESONIDE ORODISPERSIBLE TABLETS ARE HIGHLY EFFECTIVE FOR RE-INDUCTION OF CLINICAL REMISSION IN RELAPSING ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE EOS-2 TRIAL

Stephan Miehlke  et al.

Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults
Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults

Stephan Miehlke  et al.

S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease
S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease

Stephan Miehlke  et al.

THE DISEASE COURSE OF MICROSCOPIC COLITIS – A 5-YEAR PROSPECTIVE EUROPEAN INCIDENCE COHORT (PRO-MC)
THE DISEASE COURSE OF MICROSCOPIC COLITIS – A 5-YEAR PROSPECTIVE EUROPEAN INCIDENCE COHORT (PRO-MC)

Stephan Miehlke  et al.

MICROSCOPIC COLITIS NO MORE: HLA ASSOCIATION DISCRIMINATES COLLAGENOUS FROM LYMPHOCYTIC COLITIS
MICROSCOPIC COLITIS NO MORE: HLA ASSOCIATION DISCRIMINATES COLLAGENOUS FROM LYMPHOCYTIC COLITIS

Stephan Miehlke  et al.

Item 1 - 14 / 14
1